TCM
RIGL icon

Triumph Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Triumph Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$8.57K – 1884
2025
Q4 		$8.57K Buy
+200
New +$7.54K ﹤0.01% 1127

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Triumph Capital Management's RIGL Position: Q1 2026 in Review

Triumph Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 200 shares — an estimated $8.57K sold.

Triumph Capital Management first reported a position in RIGL in Q4 2025 and held it in 1 quarter. The position peaked at $8.57K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Triumph Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Triumph Capital Management sold 200 Rigel Pharmaceuticals shares in Q1 2026, an estimated $8.57K.
  • Triumph Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Triumph Capital Management's Rigel Pharmaceuticals position peaked at $8.57K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.